UNSPSC 51183407: Mitiglinide calcium hydrate

This classification denotes an anti-diabetic agent with the molecular formula 2C19H24NO3.Ca.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9651C21W3Z, chemically known as bis((2s)-2-benzyl-3-(cis-hexahydroisoindolin-2-ylcarbonyl)propionate) calcium dihydrate, d-, but more generally known as mitiglinide calcium hydrate, which bears US NIH Compound Identifier 6918235.

European Medicines Agency schedules mitiglinide calcium hydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08999MIG. Most nations, for tariff purposes, schedule mitiglinide calcium hydrate under HS 29339990. SMILES: C1CCC(CC1)C[C@@H](CC(=O)N2C[C@H]3CCCC[C@H]3C2)C(=O)[O-].C1CCC(CC1)C[C@@H](CC(=O)N2C[C@H]3CCCC[C@H]3C2)C(=O)[O-].O.O.[CA+2].

UNSPSC 51183407 Mitiglinide calcium hydrate is a Commodity code covering pharmaceutical products purchased through state and local cooperative procurement vehicles, specifically generic multi-source pharmaceuticals and over-the-counter products distributed to state agencies, local government facilities, and participating healthcare institutions. State and local governments procure this category through cooperative purchasing alliances that consolidate demand across multiple jurisdictions and authorize distribution through established pharmaceutical wholesalers, leveraging volume to negotiate competitive pricing and ensure supply-chain compliance with FDA, cGMP, and Drug Supply Chain Security Act requirements. The issuing bodies are primarily state purchasing departments administering multi-state cooperative vehicles and the participating state and local facilities they serve; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, exemplifies this structure and extends to participating jurisdictions including Oregon.

MMCAP issued a Request for Proposal on January 20, 2026, with a response deadline of March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products effective July 1, 2026, requiring vendors to supply through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with pricing weighted heavily on competitiveness (75 percent) and compliance with administrative formatting, EDI capability, and flat-fee structures (25 percent combined). Vendors must maintain comprehensive insurance including $5 million commercial general liability, demonstrate cGMP and DSCSA compliance, hold contractual relationships with at least two of the three authorized wholesalers, and accept a 3 percent administrative fee on all contract purchases, with performance penalties ranging from $200 to $1,500 per violation for late reporting or missed onboarding. The contract term runs two years for new responders with optional MMCAP extensions, or aligns with existing agreement dates through June 30, 2028 for incumbent vendors.